Advertisement
Research Article

Late Complications of Clinical Clostridium Histolyticum Collagenase Use in Dupuytren's Disease

  • Warren M. Rozen mail,

    warrenrozen@hotmail.com

    Affiliations: Department of Plastic and Reconstructive Surgery, Dandenong Hospital, Southern Health, Dandenong, Victoria, Australia, Department of Surgery, Faculty of Medicine, Monash University, Clayton, Victoria, Australia

    X
  • Yasith Edirisinghe,

    Affiliations: Department of Plastic and Reconstructive Surgery, Dandenong Hospital, Southern Health, Dandenong, Victoria, Australia, Department of Surgery, Faculty of Medicine, Monash University, Clayton, Victoria, Australia

    X
  • John Crock

    Affiliations: Department of Plastic and Reconstructive Surgery, Dandenong Hospital, Southern Health, Dandenong, Victoria, Australia, Department of Surgery, Faculty of Medicine, Monash University, Clayton, Victoria, Australia

    X
  • Published: August 17, 2012
  • DOI: 10.1371/journal.pone.0043406

Reader Comments (1)

Post a new comment on this article

Utilizing the results

Posted by mffreshwatermd on 05 Nov 2012 at 12:37 GMT

As a hand surgeon, I am concerned about these findings in 2/12 patients experiencing these adverse events.
1. Have the authors reported their findings to the government regulators in either the TGA in Australia or the FDA in the US, where the initial trials were done?
2. In which public database is this trial registered?
3. Based on these findings have the authors decided to stop the trial?

No competing interests declared.

RE: Utilizing the results

MattJHodgkinson replied to mffreshwatermd on 06 Nov 2012 at 10:05 GMT

The article has been retracted, see http://www.plosone.org/an...

Competing interests declared: I am an Associate Editor for PLOS ONE